10. シャルコー・マリー・トゥース病 Charcot-Marie-Tooth disease Clinical trials / Disease details
臨床試験数 : 39 / 薬物数 : 44 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-001150-15-FR (EUCTR) | 14/03/2016 | 02/03/2016 | SERENDEM study: high dose biotin in patients suffering from disability related to peripheral nerve diseases | SERENDEM study: MD1003 in patients suffering from demyelinating neuropathies, an open label pilot study | chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating neuropathy associated with immunoglobulin M (IgM) monoclonal gammopathy and antibodies against myelin-associated glycoprotein (MAG), Charcot Marie Tooth Ia (CMT Ia) neuropathy MedDRA version: 18.1;Level: LLT;Classification code 10066137;Term: Anti-MAG neuropathy;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.1;Level: PT;Classification code 10057645;Term: Chronic inflammatory demyelinating polyradiculoneuropathy;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: biotin Product Code: MD1003 INN or Proposed INN: D-BIOTIN | MEDDAY PHARMACEUTICALS | NULL | Not Recruiting | Female: yes Male: yes | 15 | Phase 2 | France |